Can Healthcare Stocks Continue their 2018 Rally?

Investors looking for defensive investments in an uncertain world may benefit from looking at healthcare stocks, which was the best-performing sector in 2018

David Brenchley 30 January, 2019 | 8:07AM

Drugs, tablets, pharmaceuticals, healthcare, defensive investments

In an uncertain environment for both risk assets and economies, it may be prudent for investors to look towards more defensive investments.

Clearly, there are a number of non-equity-heavy asset classes that can do the job – infrastructure being one, gold another. But for those keen to stay risk-on and in equities, healthcare also has defensive qualities.

SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk

To view this article, become a Morningstar Basic member.

Register For Free

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar
Rating
Amgen Inc224.13 USD0.00
Bristol-Myers Squibb Company59.81 USD0.00
Carmignac Pf Patrimoine F GBP Acc126.80 GBP1.37
Celgene Corp  
Eli Lilly and Co150.65 USD0.00
International Biotechnology Ord772.02 GBP0.52
Intuitive Surgical Inc572.39 USD0.00
Polar Capital Healthcare Opports Inc37.00 USD1.47
Quest Diagnostics Inc118.07 USD0.00
Stryker Corp195.35 USD0.00
Takeda Pharmaceutical Co Ltd4,163.00 JPY0.00
TB Evenlode Global Income B GBP Acc1.28 GBP2.47

About Author

David Brenchley

David Brenchley  is a Reporter for Morningstar.co.uk

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites
© Copyright 2020 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Member User Agreement        Cookies